Do you have IgAN?
Learn more about an IgAN clinical trial and see if it's a fit for you.

The ALN-CC5 IgAN trial is researching an investigational medication called cemdisiran (cem-DEE-si-ran).

In people with IgAN, a protein called IgA builds up in the kidney causing inflammation. This may lead to kidney damage that causes protein from the blood to leak into urine.

This trial is investigating if cemdisiran can decrease inflammation in the kidney and potentially reduce the amount of protein that the kidney leaks.

We are looking for people who are:
- 18 to 65 years old
- Diagnosed with IgAN
- Vaccinated or willing to receive vaccinations for meningitis, Hib, and pneumonia (provided at no cost)

Additional medical information and tests will be performed to confirm eligibility.

What should I expect?

**Observation Period**
4-6 months
No study injections

**Initial Study Treatment Period**
9 months
Monthly injections
- 2 in 3 chance of receiving cemdisiran
- 1 in 3 chance of receiving placebo

**Extended Study Treatment Period**
12 months
Monthly injections
Everyone receives cemdisiran

**Follow-up**
12 months
Visits every 3 months
No study injections

Maximum time in the ALN-CC5 IgAN trial is just over 3 years
There are no invasive or imaging procedures (biopsies or X-rays) required for the study.

Interested in learning more?
Please email us at clinicaltrials@alnylam.com for additional information.